A Farnesyl-Protein Transferase Inhibitor Induces p21 Expression and G1 Block in p53 Wild Type Tumor Cells*

Laura Sepp-LorenzinoDagger and Neal Rosen

From the Program in Cell Biology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Farnesylation is required for the membrane partition and function of several proteins, including Ras. Farnesyl-protein transferase inhibitors (FTIs) were developed to prevent Ras processing and thus to be effective agents for the treatment of cancers harboring mutated ras. However, FTIs inhibit the growth of most tumor cells and several xenograft models, irrespective of whether they possess mutated ras. Furthermore, the antiproliferative effect is not correlated with inhibition of Ki-Ras processing; tumors with wild type ras are inhibited, and FTIs are not particularly toxic. These data suggest that the mechanism of FTI action is complex and may involve other targets besides Ras. To begin to understand how FTIs work, we investigated the mechanism of growth inhibition. FTI causes G1 arrest in a subset of sensitive lines. This is accomplished by transcriptional induction of p21, which mediates the inhibition of cyclin E-associated protein kinase activity, pRb hypophosphorylation and inhibition of DNA replication. Induction of p21 is p53-dependent; it does not occur in cells with mutant p53 or in cells expressing human papillomavirus E6. However, neither p53 nor p21 are required for inhibition of cell proliferation. FTI still blocks the growth of cells deficient in these proteins. In the absence of p21, G1 block is relaxed, DNA replication is not affected, and cells become polyploid and undergo apoptosis. These results suggest that farnesylated protein(s) may be involved in regulating p53 function and in coordinating entrance into S, and that the consequences of FTI treatment are a function of the other mutations found in the tumor cell.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The biologic activity of some proteins is dependent upon their isoprenylation. For example, farnesylation of Ras and geranylgeranylation of small GTP-binding proteins of the Rab and Rho families are necessary for proper subcellular localization and for efficient interaction with regulators and effectors (1, 2). This led to the idea that specific inhibitors of farnesyl-protein transferase would be useful anticancer agents by virtue of their ability to prevent Ras processing (1, 3-5). Several natural products with anti farnesyl-protein transferase activity have been identified, but farnesyl-protein transferase inhibitors (FTIs)1 with little activity against related geranylgeranyl-protein transferase I, were also rationally designed (reviewed in Coleman et al. (3)). These selective agents, including the peptidomimetic FTI L-744,832 we used in our studies (6), inhibit protein farnesylation generally and Ha-Ras processing specifically. Accordingly, FTIs effectively revert the phenotype of Ha-ras-transformed fibroblasts and have remarkable effects on animal tumors that are Ha-ras-dependent (7, 8). They prevent the development of breast tumors when administered to murine mammary tumor virus-Ha-ras transgenic mice and when these tumors are allowed to develop, cause their complete remission (7, 8).

However, it is not clear that the effects of the drug are due predominantly to inhibition of Ras processing. First, the kinetics for inhibition of cell growth and initiation and maintenance of morphological reversion of v-ras-transformed fibroblasts by FTI does not correlate with the kinetics for inhibition of Ras processing (9). Second, a majority of human tumor cell lines are sensitive to FTI whether or not they contain mutated ras genes (6). Furthermore, although the processing of Ki- and N-Ras is much less sensitive to FTI than is that of Ha-Ras (10-14), tumor cell lines with the former mutations can be very sensitive to the drug (6). Finally, although FTI inhibits the processing of wild type Ha-Ras, the drug is selective for tumor cells and is remarkably nontoxic in vivo (6-8).

These observations suggest that the phenotype induced by FTI might be due to effects on other farnesylated target proteins (3-5). These include lamins, nuclear matrix proteins, Rho B, among others. In fact, Prendergast et al. (9, 15) have shown that in transformed fibroblasts the growth and morphological changes induced by FTI correlate more closely with inhibition of RhoB processing than with changes in Ras. This is unlikely to be true in epithelial lineages, however, in which inhibition of growth by FTI is unassociated with characteristic changes in morphology and cytoskeletal architecture.

The mechanism underlying FTI action is of interest for several reasons. The action of the drug is likely to be secondary to specific inhibition of farnesyl-protein transferase. This suggests that one or several farnesylated protein(s) yet to be identified (or to be assigned such a function), play a critical role in the biology of transformation. Second, several FTIs are currently entering phase I trials as anticancer agents in humans. Rational clinical development will depend on an understanding of the biochemical basis for their inhibition of cell growth. We undertook to approach these questions by examining the mechanism(s) by which FTI arrested the growth of cancer cells. We found that in a subset of sensitive lines, FTI arrests cells in either G1 or G1 and G2. In these cell lines, FTI caused a p53-dependent induction of p21waf1/cip1/sdi, which led to inhibition of cyclin E- and A-associated protein kinase activities, accumulation of hypophosphorylated retinoblastoma protein (pRb), inhibition of DNA synthesis, and cell cycle arrest. However, whereas p21 induction was necessary for G1 block, it was not necessary for the cytotoxic effects of the drug. In cells in which p53 or p21 were knocked out, FTI caused endoreduplication of DNA and increased apoptosis. These data show that FTI affects cells in a complex manner that is, as it might be expected, dependent upon the complement of mutations in cell cycle regulatory genes in the tumor cell. They also suggest that farnesylated protein(s) may be involved in regulating cellular activity of p53.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- FTI L-744,832 was a generous gift from Drs. N. Kohl and A. Oliff at Merck & Co., West Point, PA. The drug was dissolved in phosphate-buffered saline (PBS) to a final concentration of 50 mM. Stocks were fractionated and stored at -80 °C.

Cell Lines-- The human tumor cell lines MCF7, MDA MB-468, Colo 205, DU145, and PC3 were from the American Tissue Culture Collection. HCT116 p21 knockouts and parentals (16) were kindly provided by Drs. T. Waldman and B. Vogelstein (John Hopkins University, Baltimore, MD). All cells were grown in Dulbecco's modified Eagle's medium:Ham's F-12 (1:1) supplemented with 10% fetal bovine serum, 2 mM glutamine, and 50 units/ml each of streptomycin and penicillin at 37 °C in a humidified incubator with 5% CO2, air.

Cell Proliferation and Soft Agar Growth-- To investigate the effect of the FTI L-744,832 on the proliferation of MCF7 and HCT116 cells, growth curves and soft agar colony formation assays were performed as described in Sepp-Lorenzino et al. (6). In order to collect cells for cell cycle analysis and apoptosis and to obtain protein samples, cultures were seeded at a density of 2,500 cells/cm2 and incubated with or without 20 µM FTI for increasing time periods. Cells floating in the medium were collected by centrifugation, and attached cells were trypsinized. These populations were combined. The cell number was determined with a Coulter counter, and aliquots were prepared for protein and kinase analysis and determination of cell cycle parameters and apoptosis.

Flow Cytometry and Determination of Apoptosis-- Nuclei were prepared according to Giaretti and Nusse (17), stained with ethidium iodide, and analyzed with a Becton Dickinson fluorescence-activated cell sorter. Conversely, samples for whole cell flow analysis were prepared according to Nusse et al. (18). Dual label FACS analysis was employed to determine the effect of the drug on DNA replication. Thirty minutes before harvest, cells were pulsed-labeled with 10 µM bromodeoxyuridine (BrdUrd). Samples were fixed and stained with anti-BrdUrd monoclonal antibodies conjugated with fluorescein (Becton Dickinson) and with propidium iodide prior to FACS analysis.

Apoptosis was assessed with quantitative fluorescence microscopy and terminal deoxynucleotidyl transferase assays combined with flow cytometry. Terminal deoxynucleotidyl transferase assays were performed with the apo-BrdUrd kit from Pharmingen according to the manufacturer's instructions.

For quantitative fluorescence microscopy, 105 cells were fixed in 3% paraformaldehyde in PBS and stored at 4 °C until further analysis. Cells were then washed with PBS and resuspended in 25 µl of PBS containing 3 µg/ml bisbenzimide. Over 300 cells were counted with a fluorescence microscope, and the percentage of apoptosis was determined.

RNA Isolation and Northern Blots-- Cells were extracted with RNAzol (Quality Biotech). Thirty µg of total RNA was analyzed by Northern blotting using a HindIII-XbaI 0.7-kilobase pair fragment of p21 cDNA as a probe (kindly provided by Dr. J. Massagué, Memorial Sloan-Kettering). The probe was labeled by random priming. Blots were also probed for a housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase) as a control for RNA loading. p21 and glyceraldehyde-3-phosphate dehydrogenase mRNA levels were quantitated with a PhosphorImager and p21 mRNA levels were normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA.

Protein Analysis-- Extracts for protein analysis were prepared from PBS-washed cell pellets that had been stored at -20 °C. Pellets were lysed with 2% SDS, for pRb detection or with 1% Nonidet P-40 for Cdk activity assays. For total cell lysates, pellets were dissolved in 2% SDS in 50 mM Tris, pH 8, boiled 10 min, and sonicated three times for 30 s each time on ice. Nonidet P-40 lysates were obtained by incubating the cell pellets on ice for 15 min in 1% Nonidet P-40, 50 mM Tris, pH 7.4, 150 mM NaCl, 40 mM NaF, 1 mM V04Na3, 10 µg/ml each of soybean trysin inhibitor, aprotinin, and leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Insoluble material was removed by centrifugation at 15,000 × g for 5 min. Protein concentration was measured with the bicinchoninic acid protein assay (Pierce). Ten percent polyacrylamide gels were used to detect cyclins, Cdks, and p21, whereas 7% gels were used for analysis of pRb. Gels were transferred onto nitrocellulose and probed with specific antibodies. All the antibodies for immunoblotting were from Santa Cruz. Protein detection was by chemiluminescence (ECL, Amersham Corp.).

In Vitro Kinase Reactions-- Cyclin-associated Cdk 2 and Cdc 2 protein kinase activity were assayed in vitro with histone H1 as the substrate. One-hundred µg of Nonidet P-40 lysates were immunoprecipitated with 2 µg of anti-cyclin antibodies (sc-751 for cyclin A, sc-198 for cyclin E, and sc-181 for cyclin B, Santa Cruz Biotechnology). Immune complexes were washed four times with Nonidet P-40 buffer and twice with 20 mM Tris-HCl, pH 7.4, 7.5 mM MgCl2, and 1 mM dithiothreitol. Kinase reactions were carried out for 15 min at 37 °C in 40 µl of kinase buffer containing 20 mM Tris HCl pH 7.4, 7.5 mM MgCl2, 1 mM dithiothreitol, 30 µM ATP, 10 µCi of [gamma -32P]ATP, and 2 µg of histone H1. Cdk 4 activity was analyzed in anti-Cdk 4 immunoprecipitates with a glutathione S-transferase-pRb fragment (Promega) as a substrate. Reactions were terminated by addition of 5× SDS-polyacrylamide gel electrophoreiss sample buffer and then boiled for 5 min. Proteins were separated on 10% gels and transferred onto nitrocellulose, and blots were exposed to x-ray film or to a PhosphorImager screen. Kinase activity was quantitated with a FUJIX PhosphorImager. Blots were also probed for cyclins, kinases, and p21 using specific antibodies and detection by chemiluminescence (ECL, Amersham).

Transfections-- Transient and stable transfections were carried out using Lipofectin (Life Technologies, Inc.) according to the manufacturers' instructions. Transient transfections were employed to study the effect of FTI on the induction of the p21 promoter. Luciferase reporter constructs under control of the p21 promoter, either inact (WWP) or lacking the major p53 regulatory site (DM) (19), were cotransfected with SV40-beta -galactosidase into MCF7 cells. After 16 h, cultures were split into 6-well plates and treated for either 24 or 48 h with or without 20 µM FTI in triplicate. Cells were harvested, and aliquots were employed for determination of beta  -galactosidase and luciferase activity. Luciferase activity was normalized to beta -galactosidase, which was unaffected by the FTI.

HCT116 E6 transfectants were obtained upon co-transfection of the HPV-E6-AU1 epitope tagged under the control of the SV40 promoter (pSG5-HPV-E6-AU1) (kindly provided by Dr. M. Stöppler, Georgetown University Medical Center) with a neomycin resistance-conferring plasmid (pSV40-neo). Single cell clones were obtained after 2 weeks of growth in the presence of 500 µg/ml G418. Clones were characterized by E6 expression (upon immunoprecipitation and immunoblotting with anti-AU1 antibody (BabCo)), by the lower basal levels of p53 and by the decreased induction of p53 by doxorubicin (350 nM for 24 h).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We have previously shown that FTI has a profound inhibitory effect on the anchorage-dependent and -independent growth of a majority of human tumor cell lines (6). In order to begin to identify the target(s) responsible for the antiproliferative effect of the FTI, we investigated the mechanism of growth inhibition in several of the sensitive lines identified in our previous screen (6). FTI inhibited the growth of various cell lines without apparent changes in cell cycle parameters. On the other hand, in another subset of sensitive lines, inhibition of growth was accompanied by cell cycle arrest. For example, the human breast carcinoma cell line MCF7 is sensitive to the FTI (6). These cells are estrogen-dependent human breast cancer cells, harboring wild type p53 and ras, and functional pRb; they posses low levels of epidermal growth factor receptor and ErbB2 and abundant levels of insulin-like growth factor I receptor (20). As shown in Fig. 1A, FTI inhibited MCF7 cell proliferation and resulted in an increase in the proportion of G1 cells at the expense of cells in S phase, whereas the proportion of cells in G2 and mitosis remained largely unchanged (Fig. 1B). G1 arrest was accompanied by hypophosphorylation of pRb as seen in Fig. 1C. Control cells maintained hyperphosphorylated pRb while in a logarithmic growth state; hypophosphorylation of pRb was detected at days 5 and 6 when cultures began to reach confluence.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of MCF7 cell proliferation by FTI is accompanied by G1 arrest and hypophosphorylation of pRb. A, MCF7 cells seeded onto 12-well plates at a density of 104 cells/well were or were not treated with 20 µM FTI for increasing time periods. Cells were harvested by trypsinization and counted with a Coulter counter. Each point represents triplicate wells. B, MCF7 cells seeded at 2,500 cells/cm2 were grown for up to 6 days in the presence or absence of 20 µM FTI. Cells were harvested by trypsinization, and nuclei were prepared and stained with ethidium bromide and analyzed by flow cytometry. C, MCF7 cells grown as described for B were harvested, and total cell extracts were made in SDS buffer. pRb was detected by immunoblotting on 7% polyacrylamide gels.

The mechanism by which FTI induced the hypophosphorylation of pRb and G1 block was investigated. FTI treatment led to a time-dependent inhibition of cyclin E- and A-associated kinase activities, whereas Cdk 4 kinase activity remained unchanged (Fig. 2A and not shown). The kinase activity of cyclin E·Cdk 2 complexes declined earlier than that associated with cyclin A (24 h versus 48-72 h). FTI induced a decline in the steady-state levels of cyclin A (2-3-fold) and a slight decrease in Cdk 2, which might explain the effect on kinase activity of this complex (Fig. 2B). On the other hand, the levels of Cdk 4 and cyclins E and D3 remained largely unchanged, whereas FTI increased cyclin D1 levels by 2-3-fold (Fig. 2B).


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 2.   FTI induces the inhibition of cyclin E- and A-associated kinases in MCF7. Cells grown as described for Fig. 1B were harvested and washed with PBS, and protein extracts were made in 1% Nonidet P-40 lysis buffer. A, the kinase activity of cyclin E- and A-containing complexes was assayed in vitro with histone H1 as a substrate. B, steady-state levels of cyclins and Cdks were analyzed by electrophoresis on 10% SDS-polyacrylamide gels and immunoblotting with specific antibodies.

As cyclin E kinase levels fell in the absence of major changes in cyclin E and Cdk 2 expression, the effects of FTI on the expression of Cdk inhibitors (Cdi) were determined. No changes were observed in the levels of p27, p15, p16, p18, and p19 (not shown); however, p21waf1/cip1/sdi was induced by treatment of MCF7 cells with 20 µM FTI (Fig. 3A). We also found that p21 levels rose with increased cell density in control cultures, yet the levels induced by FTI treatment are 2.5-5-fold higher than those of controls. It is also important to point out that the cell density in FTI-treated cultures remained very low compared with control cultures (Fig. 1A), thus if a direct comparison could be made under equal density conditions the induction of p21 by FTI would be of a greater magnitude.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Up-regulation of p21waf1/cip1/sdi by FTI treatment. A, MCF7 cell lysates were prepared as described for Fig. 2A, and p21 was detected on total cell extracts by immunoblotting with anti-p21 antibodies. Quantitation was performed with a Bio-Rad image analyzer. B, time course for p21 induction by FTI and doxorubicin. C, p21 mRNA levels were analyzed by Northern blotting and normalized to the levels of glyceraldehyde-3-phosphate dehydrogenase.

The kinetics of induction of p21 by FTI were compared with those of doxorubicin, an agent known to induce DNA damage and p21. Cells were treated for increasing time periods with either 20 µM FTI or 350 nM doxorubicin and p21 levels were compared with those of untreated controls (Fig. 3B). Doxorubin induced a rapid and marked increase in the steady-state levels of p21, detected after 3 h of drug treatment. In contrast, FTI induction took at least 16 h to become evident. A maximun p21 level was attained after 24 h in FTI when p21 was 5-fold higher than that in untreated controls. The induction of p21 by the FTI was accompanied by an increase in the steady-state levels of p21 mRNA (Fig. 3C). Increased p21 mRNA was also detected in control cultures as cell density increased; however, FTI induction was 4-fold greater (484 versus 2012 arbitrary units).

We observed that the cells in which FTI induced p21 and caused G1 arrest had wild type p53. MCF7 and human colon carcinoma HCT116 are both p53 wild type cells, and in both, FTI treatment leads to increased p21, Cdk inhibition, Rb hypophosphorylation, and cell cycle block (Figs. 1, 2, and 6). On the contrary, FTI did not induce p21 in cell lines with mutated p53 (such as Colo 205, DU145, PC3, and MDA MB-468) that are sensitive to its effects on cell growth (Fig. 4A). In view of these results we sought to determine whether the induction of p21 in response to the FTI was dependent on p53.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   p21 up-regulation by FTI is dependent on p53 function. A, a set of p53 positive and negative cell lines was tested for the ability of 20 µM FTI to induce p21 as described for Fig. 3. B, activation of the p21 promoter by FTI requires an intact p53-binding site and wild type p53 activity. MCF7 (p53+/+) and MDA MB 468 (p53 mut) cells were transiently transfected with reporter constructs driven by the full-length p21 promoter (WWP) or a truncated promoter lacking the major p53 regulatory site (DM). Twenty-four h after transfection, cells were treated for an additional 24 or 48 h with or without 20 µM FTI. Luciferase activity was normalized to the activity of cotransfected SV40-beta -galactosidase. Each point was done in triplicate. The graph represents the average of three independent experiments for the 24-h time point. At 48 h of treatment proportional results were obtained.

The effect of the FTI on the transcriptional activation of the p21 promoter and its p53 dependence were investigated using a set of reporter constructs in which the luciferase gene was driven either by the intact p21 promoter (WWP-luc) or by a truncated p21 promoter, in which the major p53-binding element at -2.4 kilobase pairs is missing (DM-luc) (19). Transcription from the wild type p21 promoter was induced by the FTI in p53 wild type cells, but not in cells with mutant p53 (Fig. 4B). In addition, the p53 binding site was necessary for transcriptional activation from the p21 promoter by FTI, as no significant changes in transcription were detected from the truncated promoter in p53 wild type cells treated with FTI (Fig. 4B).

The requirement for p53 was further investigated by assessing the effects of FTI on cells engineered to express the E6 gene of the human papilloma virus 16 (HPV16). HPV16 E6 specifically targets p53 for degradation via the ubiquitin-dependent pathway (21). E6 was introduced into HCT116 cells and stable transfectants were isolated 2 weeks later as G418-resistant clones. Expression of E6 was confirmed by immunodetection of the AU1-tagged protein. These clones contained decreased basal levels of p53, and the up-regulation of p53 following DNA damage was attenuated (Fig. 5A). The induction of p21 by doxorubicin was decreased in the E6-expressing clones compared with neomycin-resistant controls, and no increase in p21 occurred in response to the FTI (Fig. 5A). Moreover, the small increase in p53 levels detected in the neomycin controls treated with FTI was absent from the p53 deficient cells. These results support the conclusion that the FTI induces the transcriptional activation of the p21 gene by a p53-dependent mechanism.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 5.   Wild type p53 function is necessary for p21 up-regulation by the FTI, but neither p53, nor p21, are required for the antiproliferative effect of FTI. A, wild type p53 function was disrupted in HCT116 cells by expression of the HPV16 E6 protein. E6-expressing clones were tested for basal and drug-induced p53 and p21 levels. Cultures were treated for 24 h with 350 nM doxorubicin and for 48 h with 20 µM FTI. p21 and p53 were immunodetected in cell extracts with specific antibodies. B, FTI inhibited the growth of cells independently of the presence of functional p53 and p21. The effect of FTI was tested on the anchorage-dependent and -independent growth of HCT116 paired cultures, either lacking p53 (neomycin controls versus HPV16 E6 expressors) or p21 (parental versus p21 knockout cells).

Are p21 and p53 required for the antiproliferative effect of the FTI? For this purpose we tested the effect of the FTI on the anchorage-dependent and -independent growth of HCT116 cells expressing HPV16 E6 or lacking the p21 gene (16). As seen in Fig. 5B, inability of the FTI to induce p21 due to absence of the gene or to loss of wild type p53 function did not alter the capacity of the drug to inhibit cell growth. This result is in agreement with our previous finding that FTI effectively inhibited the proliferation of cells with mutated p53 (6). Thus, it seems that p21 induction constitutes only one of the pathways through which FTI inhibits cell growth. If that is the case, what is the mechanism of growth inhibition in the absence of p21? We compared the effects of the FTI on HCT116 parental cells and on their counterparts lacking p21. As expected, only the parental cells could up-regulate p21 in response to FTI treatment and induce the hypophosphorylation of Rb (Fig. 6A). Increased cellular levels of p21 led to enhanced association of the Cdi with cyclin-Cdk complexes and consequential inhibition of cyclin E- and A-associated kinase activity (Fig. 6B). In contrast, in p21-/- cells the FTI neither caused decreased Cdk activity or pRb hypophosphorylation (Fig. 6, A and B). These results suggest that the inhibition of cyclin E-associated protein kinase activity and induction of Rb hypophosphorylation by FTI require the p53-dependent induction of p21.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 6.   Up-regulation of p21 is necessary for the FTI-induced hypophosphorylation of Rb, for the inhibition of cyclin E- and A-associated kinase activities, and for inhibition of DNA replication. Parental and p21 knockout cells were seeded at 2,500 cells/cm2 and treated with 20 µM FTI for increasing time periods. A, p21, p53, and Rb were detected by immunoblotting with specific antibodies and B, the activity of Cdk·cyclin complexes was assayed as in Fig. 2. Immunoprecipitates were immunoblotted for p21. C, cultures treated or not with 20 µM FTI for 72 h were pulsed-labeled with BrdUrd for 30 min prior to harvesting. Dual-stain immunofluorescence was conducted by detecting incorporated BrdUrd with monoclonal anti-BrdUrd antibodies and secondary antibodies conjugated to fluorescein isothiocyanate and by staining total DNA with bisbenzimide. The photographs depict representative frames. Quantitation was performed by counting over 300 cells per condition.

Induction of cell cycle block by FTI also required p21. FTI blocked DNA replication in parental cells; there were 4-fold fewer BrdUrd-positive cells in FTI-treated cultures compared with untreated controls (Fig. 6C). Conversely, p21-/- cells in which the FTI did not inhibit Cdk activity, continued to synthesize DNA in the presence of the drug (Fig. 6C). FACS analysis corroborated these results and revealed that the lack of Cdk inhibition and consequential unrestricted DNA replication was associated with the formation of polyploid cells (Fig. 7A). While the FTI caused parental cells to arrest in G1 and G2 at the expense of cells in S, the response of p21 knockout cells was different; S phase remained prominent, the G1 block was relaxed, and cells accumulated with greater than 4n DNA content. Ungated FACS analysis revealed the appearance of 8n and 16n peaks in the p21-/- cells treated with the drug (Fig. 7A). FTI also caused the development of polyploid cells in cells expressing HPV16 E6 (Fig. 7B).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 7.   p21 determines the cell cycle changes induced by FTI treatment. Paired cultures of HCT116 either A, lacking p21 (parental versus p21 knockout cells), or B, devoid of wild type p53 function (neomycin controls versus HPV16 E6 expressors), were treated or not with 20 µM FTI for 72 h, and the cell cycle was analyzed by FACS. The presence of polyploid cells was detected on ungated samples.

Bisbenzimide staining showed that parental cells exposed to the FTI were predominantly in interphase, whereas p21 knockout cultures showed an increased proportion of cells in mitosis (3.7% versus 9.25%) (Fig. 8, A-D). Double-staining with anti-tubulin antibodies provided evidence for endoreduplication in the FTI-treated p21-/- cells, as mitotic forms with four centrioles were common (Fig. 8E). However, some of these mitosis were abnormal and seemed to lead into apoptosis (Fig. 8D). Cell cycle analysis in combination with terminal deoxynucleotide transferase assays corroborated these results and suggested that inhibition of protein farnesylation in the absence of a p21-mediated cell cycle block, translates into increased vulnerability for cell death.


View larger version (131K):
[in this window]
[in a new window]
 
Fig. 8.   Increased apoptosis in HCT116 p21-/- cells treated with FTI is associated with abnormal mitosis. HCT116 p21+/+ and p21-/- cells were treated for 72 h with 20 µM FTI or left untreated, and samples were stained with bisbenzimide and anti-tubulin antibodies. Total DNA staining for p21+/+ untreated and FTI-treated (A and B), p21-/- untreated and FTI-treated (C and D). E, confocal photomicrograph of a polyploid mitotic p21-/- FTI-treated cell doubly stained with anti-tubulin-fluorescein isothiocyanate and bisbenzimide.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

FTIs were developed as drugs that would cause the specific inhibition of Ras processing and would thus be effective agents for the treatment of tumors with mutations in the ras proto-oncogene (1, 3, 4). Potent and highly specific FTIs are now available, and they have proven in preclinical studies to be promising drugs. However, contrary to expectations, FTIs inhibit the growth of tumor cells with wild type ras and inhibit the processing of this protein while causing only minor toxicity to normal tissue (6-8). Moreover, FTIs inhibit the growth of tumor cells containing mutations in the Ki-ras gene (6) at doses that inhibit the processing of Ha-Ras but not Ki-Ras (10-14).2 These data suggest both that FTI may exert its effects on cancer cells by inhibiting other targets (for example, Rho B (9, 15, 22)) and that the role played by activated Ras in human epithelial tumors is poorly understood. We undertook studies to determine the mechanism of induction of growth inhibition by FTI in order to develop a context in which to investigate these issues.

Most tumor cell lines, which were sensitive to the FTI in terms of inhibition of growth, did not undergo a cell cycle specific growth arrest in response to the drug. However, a subset of sensitive lines did block in G1 or in G1 and G2. These results are in agreement with the recent observations of Sebti and collaborators (23, 24). They compared the cell cycle effects of the farnesyl-protein transferase inhibitor FTI-277 and of a geranylgeranyl-protein transferase I inhibitor in human tumor cell lines. Unlike inhibition of protein geranylgeranylation, which caused a G0/G1 arrest in all cell lines examined, inhibition of farnesylation resulted in either no effect, or in G1 or G2/M blockade, in a cell line-specific fashion.

We concentrated our efforts in trying to understand whether there was a pattern that would explain the cell cycle-specific effects of the FTI. We found that cell lines that arrested in G1 (or in G1 and G2/M), were wild type for p53. The three p53-wild type human tumor cell lines we studied, MCF7 (breast), HCT116 (colon), and LNCaP (prostate), arrested in G1 in response to FTI treatment (Figs. 1B, 6B, and 7).3 The only other cell line in our inventory that is p53 wild type is the immortalized human breast epithelial line MCF10A. However, we have previously shown (6) that untransformed cells are severalfold more resistant for growth inhibition than cancer lines, thus, at 20 µM FTI no cell cycle effects were observed (not shown).

As shown in this study for MCF7 and HCT116, growth arrest was associated with activation of p53, inhibition of cyclin E-dependent protein kinase, and hypophosphorylation of the Rb protein. Inhibition of cyclin E·Cdk 2 occurred prior to cell cycle arrest and in the absence of significant changes in cyclin E·Cdk 2 or increase in p27 expression (Figs. 2 and 6, and not shown). We investigated the mechanism of cyclin E-dependent protein kinase inhibition and found that it was mediated by a p53-dependent induction of the Cdi p21waf1/cip1/sdi.

p21 plays a crucial role in controlling G1/S progression and in coordinating the G1 and G2 checkpoints (16, 19, 26-28). Besides inhibiting Cdk activity, p21 also affects DNA replication (but not DNA repair) directly, by binding to and interfering with the role of proliferating cell nuclear antigen in replication (29-33). Moreover, p21 was also shown to regulate the activity of stress-activated protein kinases (34). We found that increased p21 was responsible for the FTI-induced inhibition of cyclin E·Cdk 2 kinase activity, which in turn resulted in decreased Rb phosphorylation, inhibition of G1/S progression and cell cycle arrest. HCT116 cells in which p21 had been knocked out no longer inhibited cyclin E-dependent protein kinase activity in response to the FTI, nor did they arrest in G1 (Figs. 6 and 7). The results strongly suggest that the primary basis for induction of G1 arrest by FTI is induction of p21.

The increase in p21 levels by the FTI was detected after 16 h of drug treatment and reached a maximum after 48 h (Fig. 3, A and B) when nuclear accumulation was evident (data not shown). Nuclear translocation of p21 following up-regulation was also detected in other cell systems (35, 36). The increase in p21 protein levels was explained, in part, by a concomitant elevation in the levels of p21 mRNA (Fig. 3C). We cannot exclude at the moment the participation of other types of posttranslational regulation as it was reported that p21 levels can be controlled by changes in protein and mRNA stability (37-39).

We also detected elevated levels of p21 in untreated cells as their growth rates decreased as a function of cell density (Fig. 3, A and B). Given that the cell density of the FTI-treated cultures is severalfold lower that that of untreated controls (Fig. 1A), the mechanism for p21 up-regulation due to FTI treatment is density-independent. Another observation from our kinetic studies is that the acumulation of p21 due to treatment with FTI is delayed compared with the increase caused by direct DNA damage inflicted with doxorubicin (Fig. 3B). It is possible that this variation reflects the two different mechanism of actions for these drugs. While the effect of doxorubicin is direct and p21 is rapidly induced, the lag time observed in FTI-treated cultures might reflect the half-life of a farnesylated protein.

FTI caused a p21-dependent G1 arrest in only a few epithelial tumor cell lines, and these all contained wild type p53. Reduction of p53 expression by introduction of E6 protein prevented FTI induction of p21 (Fig. 5A); cells expressing mutated p53 did not up-regulate p21 in response to the FTI, whereas wild type cells did (Fig. 4A), and translocated p21 into the nucleus (data not shown), an indicator of wild type p53 function (36). Second, FTI induced transcription from the p21 promoter (Fig. 4B) only in p53 wild type cells, and this required the major p53 binding site in the promoter (Fig. 4B). Deletion of the p53 binding sequence at -1.3 kilobase pairs (19) decreased the magnitude of the FTI induction (Fig. 4B). The truncated promoter might still contain a weak p53-responsive site at -75 which could account for the residual activity seen by us and others (19, 39). Third, we investigated whether FTI altered p53 levels. In MCF7 cells, p53 levels were unchanged by FTI (data not shown). However, MCF7 cells express high basal levels of wild type p53 and p53 activation is not associated with further increases in its steady-state levels (40, 41). On the contrary, HCT116 cells have low basal levels of p53, which become elevated upon DNA damage. In these cells, the FTI led to a modest induction of p53 (1.5-2-fold increase) as detected by immunoblotting (Figs. 5A and 6A). Finally, it was reported that activation of p53 is correlated with up-regulation of cyclin D1 (42-44). We did observe an increase in the steady-state levels of cyclin D1 (2-3-fold) in response to FTI treatment (Fig. 6B). The weight of the evidence is, then, that FTI induces p21 via a p53-dependent pathway. The mechanism whereby FTI activates p53 transcriptional activity is unknown. The p53 effect could result from induction of low level DNA damage, but we have no evidence for this. It is also possible that a farnesylated protein plays a role in maintaining DNA stability or functions in the p53 sensor pathway, or that the FTI suppresses a pathway that down-regulates both p53 function and DNA replication.

The majority of tumor cell lines with mutated p53 were growth inhibited by FTI, but did not arrest in G1 (6) (data not shown). It was not surprising, then, to find that when p21 was knocked out from or E6 was expressed in tumor cells with wild type p53, FTI still caused cell growth arrest and death, although it no longer caused G1 block or inhibition of DNA synthesis (Figs. 6 and 7). Instead, unscheduled endoreduplication of DNA occurred and polyploid cells underwent apoptosis (Figs. 6-8). Polyploidy was also induced in HCT116 p21-/- cells by doxorubicin and other chemotherapeutic agents (28). Although many parallels can be drawn between the response of p21-/- cells to DNA damaging agents and to the FTI, there are also differences, as FTI-treated cells entered mitosis (Fig. 8, D and E), whereas other treatments led to arrest in a "G2-like state" (16, 28). It is possible that the mismatch repair deficiency of HCT116 cells (45) may contribute to polyploidy; however, rereplication was also observed in human and mouse cells lacking p53, Rb, or p21 when treated with drugs that interfere with mitotic spindle assembly (25, 46). In addition to allowing cells to continue to cycle, loss of checkpoint control under these conditions is associated with bulk replication of DNA and apoptosis (25). The mechanism underlying this phenomenon is obscure.

In MCF7 and HCT116 cells, the effects of the FTI vary as a function of p53 and p21 status. This reinforces the point that the effects of perturbing particular regulatory pathways are dependent upon the cellular context. HCT116 contains mutated Ki-ras; MCF7 contains wild type ras. The effects of FTI may vary as a function of ras genotype, but in these cells, the FTI effect on cell cycle was primarily dependent on p53 status. These data suggest that the consequences of administering FTI to patients with tumors with or without mutated p53 will be different. Clinical protocols will have to stratify patients for p53 as well as ras status. Tumors with mutant p53 and wild type ras, such as some breast, prostate, and small cell lung cancers, may be especially sensitive to treatment with DNA-damaging agents in combination with FTI.

    ACKNOWLEDGEMENTS

The excellent technical assistance of Zhengping Penny Ma and Merna Timaul-Holmes is acknowledged. The authors thank Drs. Nancy Kohl, Jay Gibbs and Allen Oliff (Merck Research Laboratories) for providing the FTI and critical comments, Drs. Todd Waldmann and Bert Vogelstein (John Hopkins University) for the HCT 116 p21 knockout cells, Diane Domingo (Sloan-Kettering Institute) for FACS analysis, Dr. Katia Manova from the Molecular Cytology Core Facility (Sloan-Kettering Institute) for invaluable help with fluorescence microscopy, Susan Krueger from the Center for Biomedical Imaging Technology, University of Connecticut Health Center, for confocal microscopy, and Dr. Gabrielle Tjaden and other members of the Rosen laboratory for helpful discussions.

    FOOTNOTES

* This work was supported in part by National Institutes of Health NCI Breast SPORE program grant (to N. R.) and Career Development Award P50CA68425-02 (to L. S. L.), and by Merck & Co.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

L. S.-L. dedicates this paper to the memory of Gabriel Lorenzino Sepp.

Dagger To whom correspondence should be addressed: Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Box 333, New York, NY 10021. Tel.: 212-639-2824; Fax: 212-717-3627; E-mail: l-sepp{at}ski.mskcc.org.

The abbreviations used are: FTI, farnesyl-protein transferase inhibitor; PBS, phosphate-buffered saline; BrdUrd, bromodeoxyrudine; FACS, fluorescein-activated cell sorter.

2 L. Sepp-Lorenzino and N. Rosen, unpublished observations.

3 L. Sepp-Lorenzino, G. Tjaden, M. M. Moasser, M. Timaul-Holmes, Z. Ma, N. E. Kohl, J. B. Gibbs, A. Oliff, H. I. Scher, and N. Rosen, manuscript submittted for publication.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Gibbs, J. L., Kohl, N. E., Koblan, K. S., Omer, C. A., Sepp-Lorenzino, L., Rosen, N., Anthony, N. J., Conner, M. W., deSolms, S. J., Williams, T. M., Graham, S. L., Hartman, G. D., and Oliff, A. (1996) Breast Cancer Res. Treat. 38, 75-83[Medline] [Order article via Infotrieve]
  2. Zhang, F. L., and Casey, P. J. (1996) Annu. Rev. Biochem. 65, 241-269[CrossRef][Medline] [Order article via Infotrieve]
  3. Coleman, P. S., Chen, L. C., and Sepp-Lorenzino, L. (1997) Subcell. Biochem. 28, 363-435[Medline] [Order article via Infotrieve]
  4. Gibbs, J. B., and Oliff, A. (1997) Annu. Rev. Pharmacol. Toxicol. 37, 143-66[CrossRef][Medline] [Order article via Infotrieve]
  5. Cox, A. D., and Der, C. J. (1997) Biochim. Biophys. Acta 1333, F51-F71[CrossRef][Medline] [Order article via Infotrieve]
  6. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N., Gibbs, J., Oliff, A., and Rosen, N. (1995) Cancer Res. 55, 5302-5309[Abstract]
  7. Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E. A., DeSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., Lee, T.-J., Smith, R. L., Graham, S. L., Hartman, G. D., Gibbs, J. B., and Oliff, A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9141-9145[Abstract]
  8. Kohl, N. E., Omer, C. A., Conner, M. W., Davide, J. P., Anthony, N. J., deSolms, S. J., Guiliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G. D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. M., O'Neill, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. (1995) Nat. Med. 1, 792-797[Medline] [Order article via Infotrieve]
  9. Prendergast, G. C., Davide, J. P., DeSolms, S. J., Giuliani, E. A., Graham, S. L., Gibbs, J. B., Oliff, A., and Kohl, N. E. (1994) Mol. Cell. Biol. 14, 4193-4202[Abstract]
  10. James, G. L., Goldstein, J. L., and Brown, M. S. (1995) J. Biol. Chem. 270, 6221-6226[Abstract/Free Full Text]
  11. Lerner, E. C., Qian, Y., Hamilton, A. D., and Sebti, S. M. (1995) J. Biol. Chem. 270, 26770-26773[Abstract/Free Full Text]
  12. Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., and Garcia, A. M. (1997) J. Biol. Chem. 272, 14093-14097[Abstract/Free Full Text]
  13. Zhang, F. L., Kirschmeier, P., Carr, D., James, L., Bond, R. W., Wang, L., Patton, R., Windsor, W. T., Syto, R., Zhang, R., and Bishop, W. R. (1997) J. Biol. Chem. 272, 10232-10239[Abstract/Free Full Text]
  14. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez, O. I., James, L., Catino, J. J., Bishop, W. R., and Pai, J. K. (1997) J. Biol. Chem. 272, 14459-14464[Abstract/Free Full Text]
  15. Prendergast, G. C., Davide, J. P., Lebowitz, P. F., Wechsler, R. R., and Kohl, N. E. (1996) Cancer Res. 56, 2626-2632[Abstract]
  16. Waldman, T., Kinzler, K. W., and Vogelstein, B. (1995) Cancer Res. 55, 5187-5190[Abstract]
  17. Giaretti, W., and Nusse, M. (1994) Methods Cell Biol. 41, 389-400[Medline] [Order article via Infotrieve]
  18. Nusse, M., Julch, M., Geido, E., Bruno, S., Di Vinci, A., Giaretti, W., and Ruoss, K. (1990) Cytometry 11, 813-821[Medline] [Order article via Infotrieve]
  19. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) Cell 75, 817-825[Medline] [Order article via Infotrieve]
  20. Sepp-Lorenzino, L., Rosen, N., and Lebwohl, D. E. (1994) Cell Growth Differ. 5, 1077-1083[Abstract]
  21. Maki, C. G., Huibregtse, J. M., and Howley, P. M. (1996) Cancer Res. 56, 2649-2654[Abstract]
  22. Lebowitz, P. F., Casey, P. J., Prendergast, G. C., and Thissen, J. A. (1997) J. Biol. Chem. 272, 15591-15594[Abstract/Free Full Text]
  23. Vogt, A., Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. (1997) J. Biol. Chem. 272, 27224-27229[Abstract/Free Full Text]
  24. Miquel, K., Pradines, A., Sun, J., Qian, Y., Hamilton, A. D., Sebti, S. M., and Favre, G. (1997) Cancer Res. 57, 1846-1850[Abstract]
  25. di Leonardo, A., Khan, S. H., Linke, S. P., Greco, V., Seidita, G., and Wahl, G. M. (1997) Cancer Res. 57, 1013-1019[Abstract]
  26. Elledge, S. J., Winston, J., and Harper, J. W. (1996) Trends Cell Biol. 6, 388-392[CrossRef]
  27. Deng, C., Zhang, P., Harper, J. W., Elledge, S. J., and Leder, P. (1995) Cell 82, 675-684[Medline] [Order article via Infotrieve]
  28. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1996) Nature 381, 713-716[CrossRef][Medline] [Order article via Infotrieve]
  29. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. (1994) Nature 369, 574-578[CrossRef][Medline] [Order article via Infotrieve]
  30. Strausfeld, U. P., Howell, M., Rempel, R., Maller, J. L., Hunt, T., and Blow, J. J. (1994) Curr. Biol. 4, 876-883[Medline] [Order article via Infotrieve]
  31. Flores-Rozas, H., Kelman, Z., Dean, F. B., Pan, Z.-Q., Harper, J. W., Elledge, S. J., and Hurwitz, J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8655-8659[Abstract]
  32. Luo, Y., Hurwitz, J., and Massague, J. (1995) Nature 375, 159-161[CrossRef][Medline] [Order article via Infotrieve]
  33. Podust, V. N., Podust, L. M., Goubin, F., Ducommun, B., and Hubscher, U. (1995) Biochemistry 34, 8869-8875[Medline] [Order article via Infotrieve]
  34. Shim, J., Lee, H., Park, J., Kim, H., and Choi, E. J. (1996) Nature 381, 804-806[CrossRef][Medline] [Order article via Infotrieve]
  35. Li, R., Hannon, G. J., Beach, D., and Stillman, B. (1996) Curr. Biol. 6, 189-199[Medline] [Order article via Infotrieve]
  36. Guillot, C., Falette, N., Paperin, M. P., Courtois, S., Gentil-Perret, A., Treilleux, I., Ozturk, M., and Puisieux, A. (1997) Oncogene 14, 45-52[CrossRef][Medline] [Order article via Infotrieve]
  37. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. (1995) Genes Dev. 9, 935-944[Abstract]
  38. Xu, C., Meikrantz, W., Schlegel, R., and Sager, R. (1995) Proc Natl Acad Sci U. S. A. 92, 7829-7833[Abstract]
  39. Li, X.-S., Rishi, A. K., Shao, Z.-M., Dawson, M. I., Jong, L., Shroot, B., Reichert, U., Ordonez, J., and Fontana, J. A. (1996) Cancer Res. 56, 5055-5062[Abstract]
  40. Vojtesek, B., and Lane, D. P. (1993) J. Cell Sci. 105, 607-612[Abstract/Free Full Text]
  41. Takahashi, K., and Suzuki, K. (1993) Int J Cancer 55, 453-458[Medline] [Order article via Infotrieve]
  42. Del Sal, G., Murphy, M., Ruaro, E., Lazarevic, D., Levine, A. J., and Schneider, C. (1996) Oncogene 12, 177-185[Medline] [Order article via Infotrieve]
  43. Chen, X., Bargonetti, J., and Prives, C. (1995) Cancer Res. 4257-4263
  44. Spitkvosky, D., Steiner, P., Gopalkrishnan, R. V., Eilers, M., and Jansen-Durr, P. (1995) Oncogene 10, 2421-2425[Medline] [Order article via Infotrieve]
  45. Parsons, R., Li, G.-M., Longley, M. J., Fang, W.-H., Papadopoulos, N., Jen, J., de Chapelle, A., Kinzler, K. W., Vogelstein, B., and Modrich, P. (1993) Cell 75, 1227-1236[Medline] [Order article via Infotrieve]
  46. di Leonardo, A., Linke, S. P., Clarkin, K., and Wahl, G. M. (1994) Genes Dev. 8, 2540-2551[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.